| P50 | author | Curie Ahn | Q16084618 |
| P2093 | author name string | Jong Cheol Jeong | |
| | Junho Chung | |
| | Eun Young Song | |
| | Hee Jung Jeon | |
| | Myung-Gyu Kim | |
| | Jaeseok Yang | |
| | Tai Yeon Koo | |
| | Hyuk Yong Kwon | |
| | Miyeun Han | |
| | Ji Won In | |
| | Hye Jin Im | |
| | Enkthuya Jambaldorj | |
| P2860 | cites work | A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation | Q35008036 |
| | CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 |
| | Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients | Q36126901 |
| | Liver transplantation with a strongly positive crossmatch: case study and literature review | Q38116841 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch | Q42214147 |
| | Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation | Q43181339 |
| | Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab | Q43873334 |
| | Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice | Q44049579 |
| | Risk for BK viremia and nephropathy after desensitization | Q44487102 |
| | Management of patients on the waiting list for deceased donor kidney transplantation | Q45008126 |
| | Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 |
| | Rituximab and intravenous immune globulin for desensitization during renal transplantation | Q46477840 |
| | Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. | Q47194132 |
| | Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin | Q50132009 |
| | Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. | Q53506317 |
| | The effect of desensitization protocols on human splenic B-cell populations in vivo. | Q53575915 |
| | Survival analysis: time-dependent effects and time-varying risk factors. | Q53778069 |
| | Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation | Q83426716 |
| | Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients | Q84596458 |
| | Roles of Toll-like receptors in allogeneic islet transplantation | Q85496488 |
| | Prospective iterative trial of proteasome inhibitor-based desensitization | Q86384946 |
| | Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab | Q86430331 |
| | Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients | Q87763662 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | desensitization | Q2700499 |
| P304 | page(s) | e2635 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation | |
| P478 | volume | 95 | |